New Drug Formulations – For Patients or Profits?
Wang et al., in a JAMA Network Research Letter, recently reviewed Medicaid expenditures on adalimumab (ADA), sold under the brand name HUMIRA®. They noted that the introduction of the citrate-free formulation cost an extra $4.4B to Medicaid between 2014 and 2021.


